Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

Evaluate the effects of topical C-82 in a psoriasis plaque test.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prism Pharma Co., Ltd.
• Treatments: Betamethasone; Calcipotriene

Criteria

Inclusion Criteria:

• mild to moderate chronic stable plaque type psoriasis

• plaques thickness of at least 200 µm

• lesion(s) on the trunk or extremities (excluding palms/soles)

• skin must be without disease findings

Exclusion Criteria:

• other skin disease

• psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis arthropathica and pustular psoriasis

• treatment with any locally acting medications (including anti-psoriatics like vitamin D analogues, dithranol) within 2 weeks preceding and during the trial

• treatment with any systemic medications (including anti-psoriatics like corticosteroids, cytostatics or retinoids) or medications which are known to provoke or aggravate psoriasis (e.g. beta-blocker, anti-malarial drugs, lithium) or phototherapy/PUVA within 4 weeks preceding and during the trial

• treatment with any biologics within 3 months preceding and during the trial

• known allergic reactions, irritations or sensitivity to the active ingredients or other components of the investigational products (e.g. Carbomere 940, propylene glycol)

• drug or alcohol abuse

• symptoms of a clinically significant illness within 4 preceding and during the trial

• participation another clinical trial within 4 weeks of this clinical trial